Impact of Predilation Before Transcatheter Aortic Valve Implantation with New-Generation Devices
Highlights
- • Significant aortic stenosis can be effectively treated with transcatheter aortic valve implantation (TAVI) in patients at high or intermediate surgical risk. While, predilation is often performed to facilitate TAVI implantation, its risk-benefit balance with new-generation devices is detabed.
- • We queried the prospective multicenter RISPEVA Study, comparing patients with vs without predilation receiving Acurate, Evolut, Lotus, Portico, or Sapien3, including a total of 1409 subjects, 1055 (74.9%) receiving predilation, and 354 (25.1%) undergoing direct TAVI.
- • After unadjusted and adjusted analysis, we found that TAVI without predilation is not associated with adverse procedural, clinical or echocardiographic results when new-generation devices are used. Predilation may however reduce procedural time with Evolut and Portico devices.
Abstract
Background
Significant aortic stenosis can be effectively treated with transcatheter aortic valve implantation (TAVI) in patients at high or intermediate surgical risk. Predilation is often performed to facilitate TAVI implantation, but its risk-benefit balance with new-generation devices is detabed. We aimed to appraise whether predilation is still needed with new-generation devices for TAVI.